Loading...
OTCM
FDMDF
Market cap1.57bUSD
Oct 14, Last price  
2.70USD
Name

4DMedical Ltd

Chart & performance

D1W1MN
OTCM:FDMDF chart
P/E
—
P/S
328.29
EPS
—
Vol. 1Y
—
Shs. 5Y
91.96%
Rev. 5Y
100.68%
Div Yld LY
—
Div Yld TTM
—
Revenues
7m
+20.64%
252,811350,8901,925789,259695,0001,232,501216,9781,054,300718,5813,754,2565,853,4017,061,546
Net income
-204m
L+579.87%
-139,029-796,268-3,973,937-3,936,980-6,491,005-21,975,379-21,420,531-24,592,876-31,459,798-35,978,672-30,069,854-204,435,909
CFO
-31m
L-9.28%
-40,940-703,000-2,158,364-3,378,717-5,778,913-7,650,348-14,520,004-25,269,278-22,652,694-30,866,882-34,475,433-31,274,940

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software. Additional products include Permetium, a preclinical imaging system designed to quantify localized changes in pulmonary function, and the AccuVent 200, a ventilator specifically tailored for small animals. Established in 2012, 4DMedical Limited is headquartered in Carlton, Australia.

Key people

Lilian Bianchi
Non-Executive Chairman of the Board · since 2023
Andreas Fouras
Chief Executive Officer, Managing Director, Executive Director
Company Secretary · since 2025
Geraldine Mcginty
Non-Executive Director · since 2023
Robert Figlin
Non-Executive Independent Director · since 2016
Julian Sutton
Non-Executive Independent Director · since 2017
IPO date
Aug 07, 2020
Employees
131
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT